$MANE News

Needham Initiates Coverage of Veradermics (MANE) with Buy Recommendation

Needham Initiates Coverage On Veradermics with Buy Rating, Announces Price Target of $136

Veradermics To Present Topline Results From Phase 2/3 '302' Study Of VDPHL01 At 2026 World Congress For Hair Research On May 30

Veradermics To Present Two Comparative Analyses Of VDPHL01's Phase 2 Male Data Results Versus Published Data On Efficacy Of Existing Minoxidil Formulations At 2026 Music City SCALE

Veradermics (MANE) Price Target Increased by 39.48% to 128.52

Veradermics (MANE) Price Target Increased by 15.32% to 92.14

Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis

Veradermics Launches Proposed Public Offering Of 3,350,000 Shares Of Common Stock

Veradermics Launches Proposed Public Offering Of 3,350,000 Shares Of Common Stock

Veradermics, Incorporated (MANE) Discusses Positive Topline Results from Phase 2/3 Study of VDPHL01 for Mild-to-Moderate Pattern Hair Loss Transcript

Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains

Veradermics, Incorporated (MANE) Discusses Positive Topline Results from Phase 2/3 Study of VDPHL01 for Mild-to-Moderate Pattern Hair Loss - Slideshow

Veradermics shares are trading higher after the company announced that its VDPHL01 drug met all primary and key secondary endpoints and led to rapid and robust hair growth.

Veradermics Reports Phase 2/3 Data For VDPHL01; Shows Significant Hair Growth Gains (30-33 hairs/cm²) And Strong Efficacy Vs Placebo In Pattern Hair Loss Treatment

Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $90

Veradermics shares are trading lower. The company reported Q4 financial results.

Veradermics Q4 EPS $(0.62) Beats $(0.66) Estimate

Veradermics To Present Three Abstracts At 2026 AAD Meeting, Including VDPHL01 Data And Patient Experience Research On Pattern Hair Loss

Veradermics, Incorporated (MANE) Presents at Leerink Global Healthcare Conference 2026 Transcript

Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal?